Compare Huntington Ingalls Industries Inc (HII) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Huntington Ingalls Industries Inc trades at $268.45 (market cap $10.64B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.5× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.04% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| HII | VRTX | |
|---|---|---|
Market Cap | $10.64B | $121.95B |
Sector | Technology | Health |
52-Week High | $453.73 | $529.59 |
52-Week Low | $252.93 | $366.54 |
Enterprise Value | $13.36B | $116.69B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $270.04, up 0.34% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company shows solid fundamentals with a P/E of 17.49 and ROE of 12.2%, supported by three consecutive quarterly earnings beats. Recent news highlights contract wins and shipbuilding milestones, reinforcing its defense sector presence. Cash flow improved to a net positive $49 million in 2026 from a net outflow of $57 million in 2025.
The outlook is cautiously optimistic given analyst consensus targets near $354.50, though technical resistance at $273 poses a near-term hurdle. Risks include execution delays on defense contracts and macroeconomic pressures on government spending. The stock offers value with a below-sector P/S of 0.82, but investors should monitor Q2 2026 earnings due July 30 for margin sustainability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
